EUR 0.3
(2.54%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 1.57 Million EUR | 180.98% |
2022 | -1.94 Million EUR | 35.5% |
2021 | -3.01 Million EUR | 64.99% |
2020 | -8.6 Million EUR | 14.64% |
2019 | -10.08 Million EUR | 39.61% |
2018 | -16.69 Million EUR | -22647.97% |
2017 | -73.39 Thousand EUR | 93.54% |
2016 | -1.13 Million EUR | -489.72% |
2015 | -192.6 Thousand EUR | -116.14% |
2014 | 1.19 Million EUR | 152.28% |
2013 | 473.05 Thousand EUR | 238.29% |
2012 | -342.08 Thousand EUR | -211.01% |
2011 | 308.14 Thousand EUR | -44.31% |
2010 | 553.35 Thousand EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2023 FY | 1.57 Million EUR | 180.98% |
2023 Q2 | 1.47 Million EUR | 0.0% |
2023 Q3 | -689.75 Thousand EUR | -146.71% |
2023 Q1 | 1.47 Million EUR | 760.31% |
2023 Q4 | -689.75 Thousand EUR | 0.0% |
2022 FY | -1.94 Million EUR | 35.5% |
2022 Q4 | -223.62 Thousand EUR | 0.0% |
2021 FY | -3.01 Million EUR | 64.99% |
2020 FY | -8.6 Million EUR | 14.64% |
2019 FY | -10.08 Million EUR | 39.61% |
2018 FY | -16.69 Million EUR | -22647.97% |
2017 FY | -73.39 Thousand EUR | 93.54% |
2016 FY | -1.13 Million EUR | -489.72% |
2015 FY | -192.6 Thousand EUR | -116.14% |
2014 FY | 1.19 Million EUR | 152.28% |
2013 FY | 473.05 Thousand EUR | 238.29% |
2012 FY | -342.08 Thousand EUR | -211.01% |
2011 FY | 308.14 Thousand EUR | -44.31% |
2010 FY | 553.35 Thousand EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Atrys Health, S.A. | -45.59 Million EUR | 103.452% |
Pharma Mar, S.A. | 1.13 Million EUR | -38.414% |
Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 99.076% |